222

EUTILEX

No trades
See on Supercharts
Market capitalization
‪79.59 B‬KRW
‪−27.72 B‬KRW
‪131.65 M‬KRW
‪25.77 M‬
Beta (1Y)
1.81

About EUTILEX

Headquarters
Seoul
Employees (FY)
89
Founded
2015
ISIN
KR7263050007
FIGI
BBG00MKJH1K4
Eutilex Co., Ltd. develops anti-tumor T cell therapy and antibody therapeutics based on proprietary immunotherapy technology. It offers T Cell Therapy, Antibody, CAR-T Cell Therapy. The company was founded by Kwon Byoung S on February 27, 2015 and is headquartered in Seoul, South Korea.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 263050 is 2140 KRW — it has decreased by 2.51% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange EUTILEX stocks are traded under the ticker 263050.
263050 stock is 6.92% volatile and has beta coefficient of 1.81. Check out the list of the most volatile stocks — is EUTILEX there?
Yes, you can track EUTILEX financials in yearly and quarterly reports right on TradingView.
263050 stock has fallen by 8.55% compared to the previous week, the month change is a 21.90% fall, over the last year EUTILEX has showed a 60.73% decrease.
263050 net income for the last quarter is ‪−7.21 B‬ KRW, while the quarter before that showed ‪−5.64 B‬ KRW of net income which accounts for −27.72% change. Track more EUTILEX financial stats to get the full picture.
Today EUTILEX has the market capitalization of ‪79.58 B‬, it has decreased by 6.21% over the last week.
No, 263050 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 263050 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EUTILEX stock right from TradingView charts — choose your broker and connect to your account.
263050 reached its all-time high on Mar 18, 2019 with the price of 41385 KRW, and its all-time low was 2310 KRW and was reached on Oct 30, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 89.00 employees. See our rating of the largest employees — is EUTILEX on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EUTILEX technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EUTILEX stock shows the sell signal. See more of EUTILEX technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EUTILEX EBITDA is ‪−25.96 B‬ KRW, and current EBITDA margin is ‪−19.72 K‬%. See more stats in EUTILEX financial statements.